Last reviewed · How we verify
NCT06576700: EcoVitis
Effect of Procyanidins in Leaky Gut Repairing in IBD
NA trial testing Grape Seed Extracts in Ulcerative Colitis in Remission in 25 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | University of Padova |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 15 June 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 12 June 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Grape Seed Extracts — full drug profile →
Conditions studied
- Ulcerative Colitis in Remission — all drugs for Ulcerative Colitis in Remission →
Sponsor
University of Padova
Who can join
Adults 18 to 80, any sex, with Ulcerative Colitis in Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if the Grape Seed Extract Ecovitis, featuring low monomeric catechins content and a high concentration of oligo-polymeric procyanidins, could modulate the Gut Microbiota composition of Ulcerative Colitis patients during the remission phase. The main questions it aims to answer are: Does Ecovitis improve the microbiota composition in patients with Ulcerative colitis? Is the intestinal permeability affected? What about the variation in the quality of life? Participants will: Take 2 capsules/day of Ecovitis for eight weeks Visit the clinic two times for checkups, serum collection, and Questionaire.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Protective Effects of Grapeseed Proanthocyanidins in Ulcerative Colitis: A Pilot Study Evaluating a Potential Therapeutic Strategy.
Facchin S, Agostini E, Laparra-Ruiz E, Benvenuto G, et al · · 2026 · PMID 41598825 · DOI 10.3390/jcm15020888
Verify or expand the search:
- PubMed search for NCT06576700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ulcerative Colitis in Remission
Currently open trials in the same condition.
- NCT06642883 — Evaluation of ProLife 10 FORTE on Gut Microbiota Composition in UC Patients · NA · recruiting
Other University of Padova trials
Trials by the same sponsor.
- NCT07435064 — NURsing-led FRAILty Prevention and Care · NA · not yet recruiting
- NCT07283354 — Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia · not yet recruiting
- NCT07259460 — Effects of Dexmedetomidine Target Controlled Infusion on Patient State Index Values and Electroencephalographic Spectrum · recruiting
- NCT07385118 — Daily Fluctuations in Brain-Derived Neurotrophic Factor and Cognition: Effects of Vigorous Exercise · NA · completed
- NCT07259291 — Minto and Eleveld Remifentanil Target Controlled Infusion (TCI) Models: a Clinical Comparison · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06576700 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Padova
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06576700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing